187 related articles for article (PubMed ID: 37201267)
1. Marked central canal T2-hyperintensity in MOGAD myelitis and comparison to NMOSD and MS.
Webb LM; Cacciaguerra L; Krecke KN; Chen JJ; Sechi E; Redenbaugh V; Dubey D; Pittock SJ; Flanagan EP
J Neurol Sci; 2023 Jul; 450():120687. PubMed ID: 37201267
[TBL] [Abstract][Full Text] [Related]
2. Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders.
Sechi E; Krecke KN; Messina SA; Buciuc M; Pittock SJ; Chen JJ; Weinshenker BG; Lopez-Chiriboga AS; Lucchinetti CF; Zalewski NL; Tillema JM; Kunchok A; Monaco S; Morris PP; Fryer JP; Nguyen A; Greenwood T; Syc-Mazurek SB; Keegan BM; Flanagan EP
Neurology; 2021 Sep; 97(11):e1097-e1109. PubMed ID: 34261784
[TBL] [Abstract][Full Text] [Related]
3. Radiologic Lag and Brain MRI Lesion Dynamics During Attacks in MOG Antibody-Associated Disease.
Cacciaguerra L; Abdel-Mannan O; Champsas D; Mankad K; Krecke KN; Chen JJ; Syc-Mazurek SB; Redenbaugh V; Lopez-Chiriboga AS; Valencia-Sanchez C; Hemingway C; Tillema JM; Ciccarelli O; Pittock SJ; Hacohen Y; Flanagan EP
Neurology; 2024 May; 102(10):e209303. PubMed ID: 38710000
[TBL] [Abstract][Full Text] [Related]
4. Comparison of MRI T2-lesion evolution in pediatric MOGAD, NMOSD, and MS.
Redenbaugh V; Chia NH; Cacciaguerra L; McCombe JA; Tillema JM; Chen JJ; Lopez Chiriboga AS; Sechi E; Hacohen Y; Pittock SJ; Flanagan EP
Mult Scler; 2023 Jun; 29(7):799-808. PubMed ID: 37218499
[TBL] [Abstract][Full Text] [Related]
5. Frequency of New Silent MRI Lesions in Myelin Oligodendrocyte Glycoprotein Antibody Disease and Aquaporin-4 Antibody Neuromyelitis Optica Spectrum Disorder.
Camera V; Holm-Mercer L; Ali AAH; Messina S; Horvat T; Kuker W; Leite MI; Palace J
JAMA Netw Open; 2021 Dec; 4(12):e2137833. PubMed ID: 34878547
[TBL] [Abstract][Full Text] [Related]
6. Central vein sign and other radiographic features distinguishing myelin oligodendrocyte glycoprotein antibody disease from multiple sclerosis and aquaporin-4 antibody-positive neuromyelitis optica.
Ciotti JR; Eby NS; Brier MR; Wu GF; Chahin S; Cross AH; Naismith RT
Mult Scler; 2022 Jan; 28(1):49-60. PubMed ID: 33870786
[TBL] [Abstract][Full Text] [Related]
7. Tumefactive Demyelination in MOG Ab-Associated Disease, Multiple Sclerosis, and AQP-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder.
Cacciaguerra L; Morris P; Tobin WO; Chen JJ; Banks SA; Elsbernd P; Redenbaugh V; Tillema JM; Montini F; Sechi E; Lopez-Chiriboga AS; Zalewski N; Guo Y; Rocca MA; Filippi M; Pittock SJ; Lucchinetti CF; Flanagan EP
Neurology; 2023 Mar; 100(13):e1418-e1432. PubMed ID: 36690455
[TBL] [Abstract][Full Text] [Related]
8. Progression independent of relapses in aquaporin4-IgG-seropositive neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody-associated disease, and multiple sclerosis.
Molazadeh N; Akaishi T; Bose G; Nishiyama S; Chitnis T; Levy M
Mult Scler Relat Disord; 2023 Dec; 80():105093. PubMed ID: 37949025
[TBL] [Abstract][Full Text] [Related]
9. Myelitis in inflammatory disorders associated with myelin oligodendrocyte glycoprotein antibody and aquaporin-4 antibody: A comparative study in Chinese Han patients.
ZhangBao J; Huang W; Zhou L; Wang L; Chang X; Lu C; Zhao C; Lu J; Quan C
Eur J Neurol; 2021 Apr; 28(4):1308-1315. PubMed ID: 33220172
[TBL] [Abstract][Full Text] [Related]
10. Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody.
Dubey D; Pittock SJ; Krecke KN; Morris PP; Sechi E; Zalewski NL; Weinshenker BG; Shosha E; Lucchinetti CF; Fryer JP; Lopez-Chiriboga AS; Chen JC; Jitprapaikulsan J; McKeon A; Gadoth A; Keegan BM; Tillema JM; Naddaf E; Patterson MC; Messacar K; Tyler KL; Flanagan EP
JAMA Neurol; 2019 Mar; 76(3):301-309. PubMed ID: 30575890
[TBL] [Abstract][Full Text] [Related]
11. CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies.
Zhao-Fleming HH; Valencia Sanchez C; Sechi E; Inbarasu J; Wijdicks EF; Pittock SJ; Chen JJ; Wingerchuk DM; Weinshenker BG; Lopez-Chiriboga S; Dubey D; Tillema JM; Toledano M; Yadav H; Flanagan EP
Neurology; 2021 Sep; 97(13):e1351-e1358. PubMed ID: 34389648
[TBL] [Abstract][Full Text] [Related]
12. Brighter spotty lesions on spinal MRI help differentiate AQP4 antibody-positive NMOSD from MOGAD.
Hyun JW; Lee HL; Park J; Kim J; Min JH; Kim BJ; Kim SW; Shin HY; Huh SY; Kim W; Seo JW; Kim KH; Kim SH; Kim HJ
Mult Scler; 2022 May; 28(6):989-992. PubMed ID: 34865555
[TBL] [Abstract][Full Text] [Related]
13. Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature.
Nagireddy RBR; Kumar A; Singh VK; Prasad R; Pathak A; Chaurasia RN; Mishra VN; Joshi D
J Neuroimmunol; 2021 Dec; 361():577742. PubMed ID: 34655992
[TBL] [Abstract][Full Text] [Related]
14. Brain structural alterations in MOG antibody diseases: a comparative study with AQP4 seropositive NMOSD and MS.
Duan Y; Zhuo Z; Li H; Tian DC; Li Y; Yang L; Gao C; Zhang T; Zhang X; Shi FD; Barkhof F; Liu Y
J Neurol Neurosurg Psychiatry; 2021 Jul; 92(7):709-716. PubMed ID: 33687975
[TBL] [Abstract][Full Text] [Related]
15. Increased peripheral inflammatory responses in myelin oligodendrocyte glycoprotein associated disease and aquaporin-4 antibody positive neuromyelitis optica spectrum disorder.
Bauer A; Rudzki D; Berek K; Dinoto A; Lechner C; Wendel EM; Hegen H; Deisenhammer F; Berger T; Höftberger R; Rostasy K; Mariotto S; Reindl M
Front Immunol; 2022; 13():1037812. PubMed ID: 36451827
[TBL] [Abstract][Full Text] [Related]
16. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
[TBL] [Abstract][Full Text] [Related]
17. Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience.
Rempe T; Tarhan B; Rodriguez E; Viswanathan VT; Gyang TV; Carlson A; Tuna IS; Rees J
Mult Scler Relat Disord; 2021 Feb; 48():102718. PubMed ID: 33388560
[TBL] [Abstract][Full Text] [Related]
18. Serum Neurofilament Light and GFAP Are Associated With Disease Severity in Inflammatory Disorders With Aquaporin-4 or Myelin Oligodendrocyte Glycoprotein Antibodies.
Chang X; Huang W; Wang L; ZhangBao J; Zhou L; Lu C; Wang M; Yu J; Li H; Li Y; Zhao C; Lu J; Quan C
Front Immunol; 2021; 12():647618. PubMed ID: 33796113
[No Abstract] [Full Text] [Related]
19. Diagnostic implications of MOG-IgG detection in sera and cerebrospinal fluids.
Matsumoto Y; Kaneko K; Takahashi T; Takai Y; Namatame C; Kuroda H; Misu T; Fujihara K; Aoki M
Brain; 2023 Sep; 146(9):3938-3948. PubMed ID: 37061817
[TBL] [Abstract][Full Text] [Related]
20. Contrasting the brain imaging features of MOG-antibody disease, with AQP4-antibody NMOSD and multiple sclerosis.
Messina S; Mariano R; Roca-Fernandez A; Cavey A; Jurynczyk M; Leite MI; Calabrese M; Jenkinson M; Palace J
Mult Scler; 2022 Feb; 28(2):217-227. PubMed ID: 34048323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]